About OncoMark
OncoMark is a Healthcare company based in Dublin (Ireland) founded in 2011, and was acquired by Cepheid in December 2021. Tissue-based cancer diagnostics are developed by OncoMark. OncoMark has raised $6.72 million across 5 funding rounds from investors including Cepheid, European Commission and Enterprise Ireland. The company was acqui-hired. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics.
Company details
OncoMark was founded in 2011 and is based in Dublin, Ireland. Tissue-based diagnostics for cancer are developed by the company within the biotechnology sector. The flagship OncoMasTR qPCR assay is utilized to assess recurrence risk in early-stage breast cancer patients through gene analysis. Additional products for melanoma, colorectal cancer, and prostate cancer are under development. Operations focus on prognostic tools for oncology applications.
- Headquarters Dublin, Ireland
- Stage Acquired
- SectorsHealthcare
- Website oncomark.com
- Social LinkedIn X
- Acquired by Cepheid (Dec 2021)
Funding Insights of OncoMark
OncoMark has successfully raised a total of $6.72M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $4.5 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.72M
- Total Rounds 5
- Last Round Series A — $4.5M
- First Round $331,244
(Dec 2014)
- Investors Count 6
All 5 funding rounds of OncoMark with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2019 | $4.5M | Series A | – | Irrus Investments, Halo Business Angel Network | – |
| Feb 2017 | $2.23M | Seed | – | – | |
| Feb 2016 | $3M | Grant | – | – | |
| Sep 2015 | $3M | Grant | – | – | |
| Dec 2014 | $331,244 | Grant | – | – |
7 investors in total: 7 institutional.
Investors in OncoMark
OncoMark has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Cepheid, European Commission and Enterprise Ireland.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| irrusinvestments.com | ||||
A platform connecting angel investors to startups in Ireland. | hban.org | Ireland | ||
VC firm investing in the UK and the US | kernel-capital.com | Cork, Ireland | ||
Support is provided to Irish manufacturing and service sector businesses. | 1998 | enterprise-ireland.com | Dublin, Ireland | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Institution of the European Union responsible for upholding the EU treaties | 1958 | ec.europa.eu | Brussels, Belgium | |
Developer of molecular diagnostic testing solutions | 1996 | cepheid.com | Sunnyvale, United States |
Investor details for OncoMark
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of OncoMark
4 dated milestones of OncoMark across 10 years, from founding to its latest funding, stage changes and deals.
- Founded OncoMark is founded.
- Funding First funding round of $331K.
- Funding Latest funding round, Series A, of $4.5M.
- Exit Acquired by Cepheid.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oncomark
Complete news archive for OncoMark
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OncoMark
OncoMark was founded in 2011 and raised its 1st funding round 3 years after it was founded.
OncoMark is headquartered in Dublin, Ireland.
OncoMark is a funded company, having raised a total of $6.72M across 5 funding rounds to date. The company's 1st funding round was a Grant of $331.24K, raised on Dec 2014.
OncoMark was founded in 2011 and is based in Dublin, Ireland. Tissue-based diagnostics for cancer are developed by the company within the biotechnology sector. The flagship OncoMasTR qPCR assay is utilized to assess recurrence risk in early-stage breast cancer patients through gene analysis. Additional products for melanoma, colorectal cancer, and prostate cancer are under development. Operations focus on prognostic tools for oncology applications.
OncoMark has 7 investors. Key investors include Cepheid, European Commission, Enterprise Ireland, European Union, and Irrus Investments.
Yes. OncoMark was acquired by Cepheid in December 2021.